{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-028815","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2026-06-16T12:10:17+00:00","discovered_at":"2026-06-16T12:15:00.313576+00:00","generated_at":"2026-06-16T12:15:09.496307+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cingulate receives first US patent for ADHD drug CTx-1301 through Dec 2042","bullets":["USPTO issued Patent No. 12,653,791 covering CTx-1301 formulation and method of use through Dec 2042.","First company-owned US patent for lead ADHD asset; includes composition-of-matter and method-of-treatment claims.","Cingulate holds additional patents in 30 European territories, Australia, Canada, Israel; applications pending in Hong Kong and South Korea.","CTx-1301 is a once-daily trimodal tablet using Precision Timed Release platform; being developed under FDA 505(b)(2) pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-028815","json":"https://secwatch.observer/filing/0001493152-26-028815.json","markdown":"https://secwatch.observer/filing/0001493152-26-028815.md","text":"https://secwatch.observer/filing/0001493152-26-028815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226028815/0001493152-26-028815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226028815/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T12:15:09.496307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}